Future Developments

PL37 administered intravenously would also be a safe and effective treatment for severe chronic and acute pain from whatever origin (cancer, surgery, traumatology, visceral) without the adverse effects of opiates.

$6 Bn
The chronic pain market

Acute and chronic pain treatment via intravenous route is also a $6 Bn market in 2015 with a GDP of around 5% which Pharmaleads plans to tackle with its DENKIs.

Read next

Discover our publications
Press & media coverage
Contact & find us

Pharmaleads SA
11, rue Watt
75013 Paris

Tel: +33 (0)1 44 06 70 00
Fax: +33 (0)1 44 06 60 99

Get the access map